Lantern Pharma to Host & Participate in Two Public Webinars During October
Express News | Lantern Pharma Inc - Phase 1B/2a Trial for Recurrent GBM to Start Late 2024
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma From the FDA
Express News | Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma From the FDA
Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ...
Lantern Appoints Piers Dixon as Head of Sales
Lantern Pharma Says FDA Oks Rare Pediatric Disease Designations In MRT, RMS, And Hepatoblastoma
Express News | Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers
Lantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a Millionaire
Watching Lantern Pharma; Zacks Small Cap Research Gives Stock $26 Price Valuation
Lantern Pharma Shares Are Trading Lower. The Company Reported Q2 Financial Results.
Lantern Pharma GAAP EPS of -$0.46 Beats by $0.09
Lantern Pharma | 10-Q: Q2 2024 Earnings Report
Express News | Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates
Express News | Lantern Pharma Q2 Net Income USD -4.96 Million
Lantern Pharma Highlights Promising Preclinical Results of LP-184's Synergy With Checkpoint Inhibitors & Sensitizing Tumors That Are Non-Responsive to Anti-PD1 Therapy in Collaboration With MD Anderson at Immuno-Oncology Summit 2024
Express News | Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy With Checkpoint Inhibitors & Sensitizing Tumors That Are Non-Responsive to Anti-Pd1 Therapy in Collaboration With Md Anderson at Immuno-Oncology Summit 2024
Express News | Lantern Pharma Inc - Preliminary Results Show Consistent Safety Profiles
Express News | Lantern Pharma Inc - 3 Partial Responses Include Disappearance of Metastatic Lesions
Express News | Lantern Pharma Announces Positive Clinical Update From Ongoing Phase 2 Harmonic™ Clinical Trial for Never Smokers With Advanced Nsclc, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort